Compare EBON & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EBON | MDXH |
|---|---|---|
| Founded | 2010 | 2003 |
| Country | United States | Belgium |
| Employees | N/A | 364 |
| Industry | Semiconductors | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.0M | 15.0M |
| IPO Year | 2020 | 2021 |
| Metric | EBON | MDXH |
|---|---|---|
| Price | $1.60 | $0.15 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $0.83 |
| AVG Volume (30 Days) | 7.7K | ★ 1.7M |
| Earning Date | 08-14-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $6.81 |
| Revenue Next Year | N/A | $13.37 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.35 | $0.15 |
| 52 Week High | $4.49 | $4.63 |
| Indicator | EBON | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 37.46 | 22.87 |
| Support Level | N/A | N/A |
| Resistance Level | $2.32 | $0.64 |
| Average True Range (ATR) | 0.15 | 0.02 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 31.77 | 9.87 |
Ebang International Holdings Inc is engaged in blockchain technology and fintech, with activities also extending to the solar industry, supported by its application-specific integrated circuit (ASIC) chip designs. The Company's business mainly includes the sale of bitcoin mining machines and related accessories, telecommunication products, solar and battery storage products, cryptocurrency exchange services, cross-border payment and foreign exchange services, SaaS data visualization and analytics solutions, and rental services. It generates the majority of its revenue from cross-border payment and foreign exchange services, with its operations mainly in mainland China and Australia, which contribute the maximum revenue.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.